Global law firm Norton Rose Fulbright has advised Profil Institut für Stoffwechselforschung GmbH (Profil) on its acquisition of US based clinical research organisation Tranquil Clinical and Research Consulting Services, LLC. The transaction involved a reverse subsidiary merger and the issuance of rollover equity in the Profil parent company in Germany to the seller. It establishes Profil’s first clinical research presence in the United States, expanding its global early phase metabolic trial capabilities and supporting international drug development programmes. Tranquil is an established US clinical research organisation, providing access to a large and diverse participant population and enabling efficient recruitment for early phase trials.
Read the full article: Profil Acquires US Clinical Research Organization //
Source: https://www.nortonrosefulbright.com/en-us/news/e061fede/norton-rose-fulbright-advises-profil-on-acquisition-of-us-clinical-research-organisation